Eli Lilly and InduPro, a biotechnology company specializing in inherent and induced proximity biology, announced a strategic collaboration and licensing agreement on January 7th, 2026. InduPro will use its proximity-guided platform to assist Lilly in the discovery and development of up to three targets for novel oncology treatments.

Per the terms of the agreement, Lilly will gain access to InduPro’s AI/ML-enabled membrane interactomics platform, although InduPro will lead early discovery efforts. The deal, which is valued at up to approximately $950 million, will also see Lilly make an equity investment in InduPro, according to a company press release.

InduPro’s platform leverages Tumor Associated Proximity Antigens (TAPAs) to discover novel, disease-specific protein-target pairs. The utilization of TAPAs, which are spatially co-localized and often functionally linked to tumor-associated antigens within the tumor microenvironment, is designed to promote new therapeutic approaches for ADCs and multispecific T-cell engagers (TCEs).

“Our partnership with Lilly underscores a shared commitment to advancing a new generation of tumor-selective medicines guided by the spatial biology of cancer,” said Prakash Raman, PhD, CEO, Indupro, in the release. “TAPAs represent a fundamentally new way to think about tumor antigens, and we’re thrilled that Lilly shares our vision of leveraging proximity-based biology to enable precision multi-specific therapeutics. We believe this partnership reflects growing confidence in our differentiated, proximity-guided approach to tumor targeting and its promise to improve the design and performance of ADCs and TCEs.”